The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

A next-generation cancer vaccine has shown stunning results in mice, preventing up to 88% of aggressive and ...

STAT Wunderkind Sydney Ramirez is revealing the immune system in our nasal passages and working toward better disease ...

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.

The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq complianceSOUTH SAN FRANCISCO, Calif., Oct.

A new research paper was published in Volume 16 of Oncotarget on October 6, 2025, titled "ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL ...

Seven UCSF investigators are receiving the prestigious award for their research from the National Institutes of Health.

Background:Respiratory viruses, including influenza viruses, respiratory syncytial virus (RSV), coronaviruses, and other emerging zoonotic pathogens, remain ...

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...